Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06876506 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Identification of B Regulatory Cells by Flow Cytometry

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment opened Show 6 more changesShow less
    • Primary completion date: May 28, 2027 to May 31, 2027
    • Start date changed from estimate of Aug 1, 2026 to Jan 21, 2026
    • Eligibility criteria expanded, about 9 words
    • Study description expanded, about 8 words
    • Site details revised
    • Publications: details revised at 3 of 3 entries
  2. Start date: Feb 1, 2026 to Aug 1, 2026
    • Primary completion date: Apr 28, 2027 to May 28, 2027
    • Study completion date: Jul 31, 2027 to Sep 30, 2027
    v4
  3. Primary completion date: Feb 28, 2026 to Apr 28, 2027
    • Start date: Aug 1, 2025 to Feb 1, 2026
    • Study completion date: May 31, 2027 to Jul 31, 2027
    v3
  4. Start date: May 1, 2025 to Aug 1, 2025
    • Eligibility criteria shortened, about 1 word
    • Study description shortened, about 2 words
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this laboratory and observational study is to develop a test to quantify B-regulatory cells in blood. This will be used to detect changes in B-regulatory cell populations in pollen and insect venom allergic patients who are receiving routine allergen immunotherapy treatment. The primary question this study aims to answer is; 1). Are changes in blood B-regulatory cells associated with successful allergen immunotherapy treatment, and therefore do these changes suggest patients have developed a suitable level of allergen tolerance and reduction in their allergic symptoms upon re-exposure to the causal allergen. Patients will also be asked to complete quality of life questionnaire periodically throughout the study to determine if there are associations between variation in B-regulatory cell populations in blood and allergic symptoms experienced.
Trial Details
NCT Number NCT06876506
Lead Sponsor Hull University Teaching Hospitals NHS Trust
Collaborators: Health Education England, Wessex, University of Manchester
Conditions
(from sponsor)		 Pollen Allergy, Venom Allergy
Related terms Dust Mite Allergy, Rhinitis, Allergic, Seasonal, Venom Hypersensitivity
Enrollment 80 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov